ASCO 2021 | JAVELIN Bladder 100: duration of treatment-free interval
Srikala S. Sridhar, MD, MSc, FRCPC, Princess Margaret Hospital, Toronto, Canada, summarizes findings from the Phase 3 JAVELIN Bladder 100 trial (NCT02603432) in selected subgroups, which assessed avelumab in patients with advanced urothelial carcinoma (UC). Patients received avelumab as maintenance therapy in addition to first-line chemotherapy therapy and overall survival (OS) was improved in patients receiving avelumab regardless of the duration of the treatment-free interval. The benefits of having a treatment-free interval between chemotherapy and immunotherapy are additionally shown in the results of the KEYNOTE-361 (NCT02853305) and IMvigor130 (NCT02807636) trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Srikala S. Sridhar, MD, MSc, FRCPC has received consultancy/advisory fees from Merck, Pfizer, Roche, BMS, Bayer, Astra Zeneca, Astellas, Janssen, Seattle Genetics, and Immunomedex.
